Showing Results for
- Academic Journals (2)
From:CMAJ: Canadian Medical Association Journal (Vol. 194, Issue 45) Peer-Reviewed1 Le NVX-CoV2373 (commercialise sous le nom Nuvaxovid) est un vaccin a sous-unites proteiques contre I'infection au SRAS-CoV-2, approuve au Canada pour les adultes incapables de recevoir un vaccin a ARN messager ou qui...
From:CMAJ: Canadian Medical Association Journal (Vol. 194, Issue 35) Peer-Reviewed1 NVX-CoV2373 (marketed as Nuvaxoid) is a protein-based vaccine against SARS-CoV-2, approved in Canada for adults unable or unwilling to receive an mRNA vaccine Protein-based vaccines have a long history of use that...
Choose how you want to be alerted when new results for your search become available.
Subscribe to Gale's RSS feed to get content delivered to your favorite RSS aggregator. Copy and paste the URL below into your reader:
Tell us where to send the alert and how often you want to receive it